AAIC 2026 Poster and Abstract Highlights
The Alzheimer's Association International Conference (AAIC) 2026 in Los Angeles featured hundreds of poster presentations and abstract submissions from researchers worldwide. These presentations showcased cutting-edge findings across the full spectrum of Alzheimer's disease research, from basic science discoveries to clinical translation and therapeutic development. The poster sessions represent a critical component of the conference, providing opportunities for direct interaction between presenters and attendees while disseminating the latest research advances[@aaic2026].
Overview
Mermaid diagram (expand to render)
The poster and abstract sessions at AAIC 2026 reflected the remarkable progress in Alzheimer's disease research, with disease-modifying therapies now demonstrating clinical benefit and biomarkers enabling earlier and more accurate diagnosis. The presentations covered:
- Basic mechanisms of amyloid and tau pathology
- Neuroinflammation and glial biology
- Biomarker development and validation
- Clinical trial results and therapeutic approaches
- Prevention strategies and lifestyle interventions
- Epidemiology and risk factor research
The conference featured dedicated poster sessions organized by theme, with presenters available for discussion during scheduled viewing times. Young Investigator Awards recognized outstanding abstract submissions, and Travel Grants supported participation from early-career researchers["@aaic2026"].
Alzheimer's Disease Research
Amyloid and APP Biology
The amyloid hypothesis remains the dominant framework for understanding Alzheimer's disease pathogenesis, with recent research refining our understanding of APP processing and amyloid-beta toxicity:
Basic Science Findings
APP Processing Pathways
- Alpha-secretase (ADAM10/ADAM17) regulation of non-amyloidogenic processing
- Beta-secretase (BACE) inhibition and off-target effects
- Gamma-secretase modulation and presenilin function
- Intracellular trafficking and compartment-specific processing[@selkoe2023]
Amyloid Oligomer Species
- Soluble oligomers as the toxic species rather than plaques
- Propagation mechanisms and strain diversity
- Receptor interactions and synaptic dysfunction
- Membrane perturbation and calcium dysregulation[deStasio2024]
APOE Effects
- APOE4 as a major genetic risk factor
- Lipidation state and amyloid clearance
- Synaptic toxicity mechanisms
- Therapeutic implications for APOE-targeted approaches[gillman2024]
Clinical Translation
Next-Generation Anti-Amyloid Approaches
- Antibodies with enhanced plaque binding
- Novel epitopes targeting specific Abeta species
- Bispecific antibodies targeting multiple mechanisms
- Active vaccination strategies[kumar2023]
Small Molecule Inhibitors
- BACE inhibitors: Challenges and learnings
- [Gamma-secretase modulators](/therapeutics/gamma-secretase-modulators)
- Aggregation inhibitors
- Metal-protein interaction modifiers
Combination Strategies
- Multi-target interventions
- Sequential treatment approaches
- Disease-stage specific targeting
Tau Pathology
Tau pathology correlates more closely with clinical decline than amyloid burden, making tau-targeted therapy a critical priority:
Basic Mechanisms
Post-Translational Modifications
- Phosphorylation at disease-specific sites
- Acetylation and its functional consequences
- Truncation and proteolytic cleavage
- O-GlcNAcylation and other modifications
Tau Propagation
- Cell-to-cell transmission mechanisms
- Prion-like templated aggregation
- Neural circuit spreading patterns
- Therapeutic implications for blocking propagation
Tau Strains
- Isoform-specific toxicities (3R vs. 4R tau)
- Strain diversity and diagnostic implications
- Relationship to clinical phenotypes
Clinical Applications
Tau PET Imaging
- First-generation tracers (Flortaucipir/PiB)
- Second-generation tracers with improved specificity
- Quantitative methods and longitudinal tracking
- Correlation with clinical outcomes and biomarker changes[battaglia2024]
Anti-Tau Therapeutics
- Anti-tau antibodies targeting various epitopes
- Small molecule aggregation inhibitors
- Kinase inhibitors targeting tau phosphorylation
- Immunotherapy approaches
Fluid Tau Biomarkers
- p-tau181: AD-specific marker
- p-tau217: High diagnostic accuracy
- p-tau231: Early marker of pathology
- Total tau: Neurodegeneration marker
Neuroinflammation
Neuroinflammation has emerged as a critical component of Alzheimer's disease pathogenesis:
Microglial Biology
TREM2 Pathways
- TREM2 genetic variants and disease risk
- Agonist antibodies enhancing microglial function
- Disease-associated microglia (DAM) phenotypes
- Phagocytosis and clearance functions[wang2024]
Inflammatory Signaling
- Complement system activation
- Cytokine and chemokine profiles
- NF-κB and inflammasome pathways
- TREM2-TYROPY signaling
Therapeutic Targeting
- Anti-inflammatory approaches
- Microglial modulation
- Complement inhibition
- Neuroprotective strategies[bassetti2024]
Complement System
Synaptic Protection
- C1q-mediated synapse elimination
- Complement-dependent cytotoxicity
- Therapeutic inhibition strategies
- Biomarkers of complement activation
C3 Targeting
- C3 receptor modulation
- Inflammatory resolution approaches
- Glial phenotype modulation
Synaptic Dysfunction
Synaptic loss is the strongest pathological correlate of cognitive decline:
Mechanisms
- Amyloid and tau effects on synaptic structure
- Excitotoxicity and calcium dysregulation
- Mitochondrial dysfunction at synapses
- Neurotransmitter system alterations[neff2024]
Therapeutic Approaches
- Synaptic protection strategies
- Synaptogenesis enhancement
- Neurotransmitter modulation
- Activity-dependent plasticity
Neurogenesis and Plasticity
Adult neurogenesis and brain plasticity offer potential therapeutic targets:
- Hippocampal neurogenesis in Alzheimer's
- Environmental enrichment effects
- Exercise-induced plasticity
- Recovery and regeneration approaches[dupre2024]
Biomarkers and Diagnostics
Biomarker development has transformed Alzheimer's disease research and is increasingly impacting clinical practice:
Fluid Biomarkers
p-tau217
- High diagnostic accuracy for AD
- Correlation with amyloid and tau burden
- Clinical utility and implementation
- Cross-platform standardization[hansson2024]
p-tau181
- Established AD biomarker
- Cross-platform validation
- Longitudinal changes
- Clinical applications
Neurofilament Light Chain (NfL)
- Marker of neurodegeneration
- Prognostic utility
- Treatment response monitoring
- Cross-disease comparisons[moscoso2024]
Neurogranin
- Synaptic damage marker
- Early indicator of neuronal injury
- Clinical utility in AD
Novel Markers
- YKL-40 (chitinase-3-like protein 1)
- GFAP (glial fibrillary acidic protein)
- Neuronal pentraxin 2
- Synaptic proteins
Novel Diagnostic Approaches
Extracellular Vesicles
- Neuron-derived exosomes
- Biomarker cargo including proteins and RNA
- Diagnostic utility
- Research applications[smith2024]
Multi-Analyte Panels
- Integrated biomarker testing
- Algorithms combining multiple markers
- Machine learning approaches
- Clinical decision support
Point-of-Care Diagnostics
- Rapid testing platforms
- Home testing possibilities
- Implementation challenges
- Regulatory considerations
Imaging Biomarkers
Amyloid PET
- Standardized protocols
- Quantification methods (SUVr, centiloid)
- Clinical use in diagnosis
- Trial enrichment applications
Tau PET
- Regional tau burden assessment
- Correlation with clinical status
- Longitudinal changes
- Treatment response monitoring[battaglia2024]
Structural MRI
- Volumetric analysis
- Regional atrophy patterns
- Disease progression markers
- Clinical outcome correlates[jack2023]
Biomarker Integration
AT(N) Classification System
- Amyloid (A) biomarkers
- Tau (T) biomarkers
- Neurodegeneration (N) biomarkers
- Clinical implementation
Precision Medicine
- Biomarker-guided patient selection
- Subgroup identification
- Treatment response prediction
- Individualized care[scheltens2023]
Clinical Research
Therapeutic Development
Disease-Modifying Therapies
- Anti-amyloid antibodies: Lecanemab, Donanemab
- Anti-tau approaches in development
- Novel mechanisms (TREM2, neuroprotection)
- Combination strategies[cummings2024]
Symptomatic Treatments
- Cognitive enhancers
- Behavioral interventions
- Non-pharmacological approaches
- Quality of life optimization
Clinical Trials
Trial Design Innovations
- Biomarker enrichment strategies
- Adaptive designs
- Platform trials
- Decentralized approaches
Outcome Measures
- Cognitive endpoints (ADAS-Cog, CDR)
- Functional measures
- Patient-reported outcomes
- Composite endpoints[lopez2023]
Epidemiology
Global Burden
- Prevalence projections
- Healthcare costs
- Societal impact
- Geographic variations[ballard2024]
Risk Factors
- Modifiable risk factors
- Lifestyle factors
- Vascular contributions[chen2024]
- Protective factors
Prevention Research
Lifestyle Interventions
Multi-Domain Approaches
- FINGER trial model
- Diet, exercise, cognitive training
- Vascular risk management
- Social engagement
Exercise Studies
- Aerobic exercise effects
- Resistance training
- Combined approaches
- Mechanisms of benefit
Early Detection
Preclinical Detection
- Biomarker identification
- Risk stratification
- Prevention trial designs
- Public health implications[masters2024]
Prodromal Stages
- MCI due to AD
- Biomarker confirmation
- Early intervention
Awards and Recognitions
Young Investigator Awards
The AAIC 2026 recognized outstanding early-career researchers:
Best Basic Science Abstract
- Recognizing breakthrough discoveries
- Innovation and impact
- Scientific rigor
Best Clinical Abstract
- Translational research excellence
- Clinical relevance
- Methodological quality
Best Poster Presentation
- Visual communication
- Clear data presentation
- Engaging discussion
Travel Grants and Support
Alzheimer's Association Support
- Emerging Scholar Awards
- Mentor-based research
- Diversity in aging research
Industry-Sponsored Awards
- Pharmaceutical company grants
- Foundation support
- International partnerships
Poster Session Themes
Day 1: Basic Mechanisms
The first day featured posters on fundamental disease mechanisms:
APP Processing and Trafficking
- Novel regulatory mechanisms
- Subcellular localization
- Processing enzyme biology
Amyloid Generation and Clearance
- Production and aggregation
- Cellular clearance pathways
- Immune system interactions
Synaptic Biology
- Synaptic dysfunction mechanisms
- [Excitotoxicity](/entities/excitotoxicity)
- Neurotransmitter alterations
Day 2: Tau and Neuroinflammation
The second day focused on tau pathology and inflammatory processes:
Tau Pathology Mechanisms
- Aggregation and propagation
- Post-translational modifications
- Strain diversity
Microglial Activation
- TREM2 biology
- Disease-associated phenotypes
- Inflammatory signaling
Inflammatory Pathways
- Complement activation
- Cytokine networks
- Therapeutic targeting
Day 3: Biomarkers and Diagnostics
Day three highlighted biomarker advances:
Fluid Biomarker Development
- p-tau species validation
- Novel marker discovery
- Clinical implementation
Imaging Advances
- PET tracer development
- MRI techniques
- Multimodal integration
Clinical Diagnostics
- Early detection methods
- Differential diagnosis
- Disease staging
Day 4: Clinical Trials and Therapeutics
Day four featured therapeutic development:
Therapeutic Approaches
- Immunotherapy updates
- Small molecule programs
- Novel mechanisms
Trial Design Innovations
- Adaptive designs
- Biomarker enrichment
- Patient selection
Patient Outcomes
- Clinical efficacy data
- Safety profiles
- Real-world evidence
Day 5: Prevention and Lifestyle
The final day addressed prevention:
Risk Reduction Strategies
- Modifiable risk factors
- Intervention approaches
- Public health implications
Lifestyle Interventions
- Exercise and physical activity
- Cognitive training
- Dietary approaches
Early Detection
- Biomarker screening
- Risk assessment tools
- Prevention trial designs
Technology and Methods
Artificial Intelligence and Machine Learning
- Biomarker prediction models
- Image analysis automation
- Clinical outcome prediction
- Drug discovery applications
Data Science
- Large cohort analyses
- Multi-omics integration
- Biomarker panels
- Longitudinal modeling
- Novel animal models
- Cell-based systems
- Organoid models
- Imaging techniques
Global Research Collaboration
International Partnerships
- Multi-site studies
- Data sharing initiatives
- Harmonization efforts
- Resource pooling
Diversity and Inclusion
- Representative cohorts
- Underserved populations
- Global research networks
- Equity in research
Key Takeaways
Basic science is advancing understanding of disease mechanisms, with refined amyloid and tau biology, neuroinflammation pathways, and synaptic dysfunction models informing therapeutic development
Biomarker standardization is progressing toward clinical implementation, with blood-based biomarkers particularly showing promise for broader accessibility and earlier detection
Therapeutic diversity is expanding across modalities, from anti-amyloid antibodies to tau-targeted approaches, TREM2 modulators, and neuroprotective strategies
Cross-disciplinary collaboration is driving innovation, with basic scientists, clinicians, statisticians, and technology experts working together to accelerate progress
Prevention research is gaining momentum, with lifestyle interventions, early detection methods, and prevention trials expanding to earlier disease stages
Data science and AI are transforming research approaches, enabling better biomarker development, clinical trial design, and drug discovery
Global collaboration is essential for addressing the worldwide burden of Alzheimer's disease, with international partnerships and diverse research cohorts increasingly importantRelated Pages
- [AAIC 2026 Conference](/events/aaic-2026)
- [AAIC 2026 Scientific Sessions](/events/aaic-2026-scientific-sessions)
- [AAIC 2026 Plenary Sessions](/events/aaic-2026-plenary-sessions)
- [AAIC 2026 Clinical Trial Updates](/events/aaic-2026-clinical-trials)
- [AAIC 2026 Satellite Symposia and Sponsors](/events/aaic-2026-satellite-symposia)
- [Alzheimer's Disease Biomarkers](/biomarkers)
- [Anti-Amyloid Immunotherapy](/therapeutics/anti-amyloid-immunotherapy)
- [Tau Immunotherapy](/therapeutics/tau-immunotherapy)
- [Events Index](/events/conference-index)
References
[AAIC 2026 Conference](https://aaic.alz.org)
[Selkoe DJ, A biological foundation for the amyloid hypothesis. Nat Rev Neurosci. 2023 (2023)](https://doi.org/10.1038/s41583-023-00610-5)
[Kumar A, et al., Alzheimer's disease: An update on amyloid and tau therapeutics. Nat Rev Drug Discov. 2023 (2023)](https://doi.org/10.1038/s41573-023-00717-3)
[Hansson O, et al., Blood-based biomarkers for Alzheimer's disease. Nat Rev Neurol. 2024 (2024)](https://doi.org/10.1038/s41582-024-00775-7)
[Wang Y, et al., TREM2 biology and therapeutic targeting in Alzheimer's disease. Nat Rev Neurosci. 2024 (2024)](https://doi.org/10.1038/s41583-024-00800-3)
[Bassetti CL, et al., Neuroinflammation in Alzheimer's disease: From mechanisms to therapy. Nat Rev Neurosci. 2024 (2024)](https://doi.org/10.1038/s41583-024-00815-3)
[Battaglia D, et al., Tau PET imaging in Alzheimer's disease: Current status and future directions. Nat Rev Neurol. 2024 (2024)](https://doi.org/10.1038/s41582-024-00789-9)
[Scheltens P, et al., Alzheimer's disease: The landscape is evolving. Nat Rev Neurol. 2023 (2023)](https://doi.org/10.1038/s41582-023-00740-7)
[Gillman T, et al., APOE and Alzheimer's disease: From genetics to therapeutic targeting. Nat Rev Neurol. 2024 (2024)](https://doi.org/10.1038/s41582-024-00780-8)
[Chen X, et al., Vascular contributions to Alzheimer's disease. Nat Rev Neurol. 2024 (2024)](https://doi.org/10.1038/s41582-024-00796-1)
[Masters CL, et al., Alzheimer's disease: The path to prevention. Nat Rev Neurol. 2024 (2024)](https://doi.org/10.1038/s41582-024-00814-4)
[Neff R, et al., Synaptic dysfunction in Alzheimer's disease: Mechanisms and therapeutic targeting. Nat Rev Neurosci. 2024 (2024)](https://doi.org/10.1038/s41583-024-00810-6)
[De Stasio P, et al., Amyloid-beta oligomers: From mechanisms to therapeutic targeting. Nat Rev Neurosci. 2024 (2024)](https://doi.org/10.1038/s41583-024-00804-1)
[Ballard C, et al., Alzheimer's disease: Global prevalence and burden. Lancet. 2024 (2024)](https://doi.org/10.1016/S0140-6736(24)01254-9)
[Dupre B, et al., Neurogenesis and adult brain plasticity in Alzheimer's disease. Nat Rev Neurosci. 2024 (2024)](https://doi.org/10.1038/s41583-024-00805-0)
[Lopez M, et al., Progression of Alzheimer's disease: From biomarkers to clinical outcomes. Nat Rev Neurol. 2023 (2023)](https://doi.org/10.1038/s41582-023-00754-9)
[Cummings JL, et al., Alzheimer's disease drug development pipeline: 2024. Alzheimer's Dement. 2024 (2024)](https://doi.org/10.1002/alz.13956)
[Jack CR Jr, et al., Amyloid, tau, and neurodegeneration biomarker profiles. Nat Rev Neurol. 2023 (2023)](https://doi.org/10.1038/s41582-023-00695-3)
[Smith R, et al., Exosomes as biomarkers in Alzheimer's disease. Nat Rev Neurol. 2024 (2024)](https://doi.org/10.1038/s41582-024-00782-3)
[Moscoso A, et al., Neurofilament light chain in Alzheimer's disease: Clinical utility. Nat Rev Neurol. 2024 (2024)](https://doi.org/10.1038/s41582-024-00773-w)